RankAlpha logo
Back to Rankings

GLSI

Greenwich LifeSciencesC
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
View Chart
Current thesis
The constructive case is that FLAMINGO-01 operational momentum is improving: FDA cleared use of the first commercial GP2 lot, screening rose above 800 patients per year, the 250-patient open-label arm is fully enrolled, and company-reported early recurrence trends remain favorable versus historical benchmarks [#PR-2026-01-22] [#PR-2026-03-03] [#PR-2026-03-17].
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +21.0.
What can break
Going-concern and dilution risk remain material despite January 2026 ATM progress [#10-Q-2025-11-14] [#PR-2026-01-27].
Momentum
5
Value
41
Sentiment
100
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $24.00 · Bull $40.00 · Bear $12.00
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $47.50
Why
Momentum5 · Δ7d -2.9
Value41 · Δ7d +0.0
Sentiment100 · Δ7d +21.0
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Sentiment · See AI snapshot
Momentum
5
26% active weight
Current posture
7d trendFlat
Δ7d
-2.9
Δ21d
-17.8
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.1
Sentiment
100
34% active weight
Current posture
7d trendImproving
Δ7d
+21.0
Δ21d
+24.1
Why this grade

Composite grade C. Momentum 5.4 / Value 41.1 / Sentiment 100.0

Fundamentals (TTM)
As of 2026-07-20
Market Cap
$206.52M
Beta
1.45
Shares Out
14.68M
P/E (TTM) · Derived
-9.8
P/S (TTM)
-
P/FCF (TTM) · Derived
-15.50
Rev YoY
-
EPS YoY
+86.4%
Gross Margin
-
Op Margin
-
Net Debt
-$6.18M
Current Ratio
2.01
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology